The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss drugs in the U.S. during a congressional testimony on Tuesday. Why it matters: Lars Fruergaard Jørgensen,

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on Tuesday.

A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the drug continuously for about a year and 4 months and then stopping. It found that about two-thirds regained the weight they lost. A similarly designed study had comparable results for tirzepatide (Zepbound).